As a consumer product SleepCheck will be huge if it gets good word of mouth. Also FDA application should be painless as it will be class I with traditional 510k. ResAppDx numbers looking very disappointing though...Hopefully that doesn't tell the whole story.
- Forums
- ASX - By Stock
- RAP
- Ann: Continued Use of ResAppDx at COVID-19 Respiratory Clinic
Ann: Continued Use of ResAppDx at COVID-19 Respiratory Clinic, page-147
-
- There are more pages in this discussion • 86 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add RAP (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
RCE
RECCE PHARMACEUTICALS LTD
James Graham / Dr Alan Dunton, MD & CEO / Non-Executive Director
James Graham / Dr Alan Dunton
MD & CEO / Non-Executive Director
SPONSORED BY The Market Online